C1709323||Open-label, multicentre safety study
C3192263||vemurafenib
C3811884||BRAF(V600) mutation
C1514241||positive
C0278883||metastatic melanoma
C1522577||follow-up
C0936012||responders' analysis
C0442027||orally
C3838813||BRAF kinase inhibitor
C3192263||vemurafenib
C0683525||treatment option
C0278883||metastatic melanoma
C3811884||BRAF(V600) mutations
C3192263||vemurafenib
C1257890||population
C0683525||treatment options
C1709323||open-label, multicentre study
C3192263||vemurafenib
C0332155||untreated
C3811884||BRAF mutation
C1514241||positive
C0278883||metastatic melanoma
C0025080||cobas(Â®) 4800
C1504359||BRAF V600 Mutation Test
C0936012||exploratory analysis
C0549183||median
C1522577||follow-up
C0558681||discontinued treatment
C0877248||Adverse events
C0877248||Adverse events
C0877248||Adverse events
C0003862||arthralgia
C0002170||alopecia
C0870082||hyperkeratosis
C0877248||Adverse events
C0553723||squamous cell carcinoma of the skin
C0022572||keratoacanthoma
C0936012||exploratory analysis
C0877248||Adverse events
C1257890||population
C0743284||vemurafenib exposure
C1522577||follow-up
C3811884||BRAF(V600) mutation
C1514241||positive
C0278883||metastatic melanoma
C0008976||clinical trial
C1257890||populations
C3192263||vemurafenib